ArticleVeterinarni medicina2026
The inhibition of deep peritoneal endometriosis by Andrographolide through macrophage M1 activity in an endometriosis mice model.
Article in Veterinarni medicina, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to demonstrate that Andrographolide, an herbal immunostimulant, can influence M1 macrophages to inhibit inflammation, including the growth of endometriosis caused by inflammation. This study evaluates the effects of Andrographolide on suppressing endometriosis through M1 macrophage activity. This post-test-only experimental study involved 42 female Balb/C mice, which were divided into six groups: Group N, KN (endometriosis without therapy), and KP (endometriosis + dienogest), P1 (endometriosis with 0.05 mg/kg), P2 (endometriosis + 0.1 mg/kg Andrographolide), and P3 (endometriosis + 0.2 mg/kg Andrographolide). Peritoneal fluid was aspirated, and the peritoneum was cut and stretched to observe the extent of the endometriosis. This study compared the formation of ectopic endometrial lesions and analysed the M1/M2 ratio in each group that received standard therapy versus Andrographolide therapy. The results from peritoneal fluid flow cytometry indicated that M1 was more dominant than M2 compared with KP. The levels of M2 in the P2 and P3 groups were also significantly lower than in the KN group. This study demonstrated that Andrographolide may enhance the regulation of M1 macrophage differentiation, acting as a precursor to endometriosis growth by suppressing M2 phenotypes that promote the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.